At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,048 enrolled
Drug / intervention
GSK2340274A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
In Brief
A Phase 3 clinical trial evaluating GSK2340274A and GSK2340273A for Influenza. Completed, enrolled 4,048 participants across 38 sites in 2 countries.
Detailed Summary
The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartNov 2009
Primary CompletionJan 2011
Study CompletionFeb 2011
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartNov 9, 2009
Primary CompletionJan 10, 2011
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.8 years ago
Interventions
GSK2340274Abiological
One intramuscular injection
GSK2340273Abiological
One intramuscular injection